Biotechnology The US Food and Drug Administration has extended the review period for the biologics licensing applications (BLA) for its lentiviral vector gene therapies – betibeglogene autotemcel (beti-cel) for β-thalassemia and elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD), submitted by bluebird bio, whose shares dived more than 11% to $8.27. 18 January 2022